Insider Selling: Orthofix Medical Inc. (NASDAQ:OFIX) Insider Sells 3,728 Shares of Stock

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) insider Aviva Mcpherron sold 3,728 shares of the firm's stock in a transaction that occurred on Wednesday, June 18th. The stock was sold at an average price of $10.51, for a total transaction of $39,181.28. Following the sale, the insider now owns 46,322 shares of the company's stock, valued at approximately $486,844.22. The trade was a 7.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Orthofix Medical Stock Up 4.4%

Shares of OFIX traded up $0.46 during mid-day trading on Monday, reaching $10.80. The company had a trading volume of 524,726 shares, compared to its average volume of 282,274. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.71. The firm has a 50-day moving average price of $12.08 and a 200 day moving average price of $15.46. Orthofix Medical Inc. has a 52 week low of $10.24 and a 52 week high of $20.73. The company has a market capitalization of $423.14 million, a price-to-earnings ratio of -2.93 and a beta of 0.80.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Roth Mkm reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Orthofix Medical in a report on Wednesday, February 26th. Wall Street Zen raised shares of Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, June 14th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Orthofix Medical in a report on Wednesday, February 26th. Barrington Research began coverage on shares of Orthofix Medical in a report on Monday. They issued an "outperform" rating and a $16.00 price objective for the company. Finally, JMP Securities reissued a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $21.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OFIX. Strs Ohio bought a new position in Orthofix Medical in the first quarter worth approximately $150,000. Jane Street Group LLC purchased a new position in Orthofix Medical during the first quarter valued at $1,076,000. Dynamic Technology Lab Private Ltd purchased a new position in Orthofix Medical during the first quarter valued at $575,000. Philosophy Capital Management LLC purchased a new position in Orthofix Medical during the first quarter valued at $6,047,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Orthofix Medical by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company's stock valued at $335,000 after acquiring an additional 1,213 shares in the last quarter. Institutional investors own 89.76% of the company's stock.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.